Biomarin Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Biomarin Pharmaceutical
BMRN Stock  USD 61.44  1.18  1.88%   
Biomarin Pharmaceutical's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Biomarin Pharmaceutical's valuation are provided below:
Gross Profit
2.5 B
Profit Margin
0.1682
Market Capitalization
12 B
Enterprise Value Revenue
3.2126
Revenue
3.1 B
We have found one hundred twenty available fundamental signals for Biomarin Pharmaceutical, which can be analyzed and compared to other ratios and to its rivals. Self-guided Investors are advised to validate Biomarin Pharmaceutical's prevailing fundamentals against the trend between 2010 and 2026 to make sure the company can sustain itself down the road. As of the 25th of February 2026, Market Cap is likely to drop to about 8 B. In addition to that, Enterprise Value is likely to drop to about 9.8 B

Biomarin Pharmaceutical Total Revenue

3.38 Billion

Check Biomarin Pharmaceutical financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Biomarin Pharmaceutical's main balance sheet or income statement drivers, such as Depreciation And Amortization of 52.1 M, Interest Expense of 17.7 M or Selling General Administrative of 642.8 M, as well as many indicators such as Price To Sales Ratio of 3.36, Dividend Yield of 0.0 or PTB Ratio of 1.78. Biomarin financial statements analysis is a perfect complement when working with Biomarin Pharmaceutical Valuation or Volatility modules.
  
Build AI portfolio with Biomarin Stock
Check out the analysis of Biomarin Pharmaceutical Correlation against competitors.
To learn how to invest in Biomarin Stock, please use our How to Invest in Biomarin Pharmaceutical guide.

Biomarin Pharmaceutical Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets8 B7.6 B4.5 B
Slightly volatile
Short and Long Term Debt Total606.2 M597.2 M769.5 M
Slightly volatile
Other Current Liabilities797 M759 M274 M
Slightly volatile
Total Current Liabilities797 M759 M517.9 M
Slightly volatile
Total Stockholder Equity6.4 B6.1 B3.2 B
Slightly volatile
Property Plant And Equipment Net505 M952.5 M733.5 M
Slightly volatile
Accounts Payable284.2 M270.7 M197.4 M
Slightly volatile
Cash1.4 B1.3 B609.6 M
Slightly volatile
Non Current Assets Total3.8 B3.6 B2.5 B
Slightly volatile
Non Currrent Assets Other290.9 M277 M137.2 M
Slightly volatile
Cash And Short Term Investments1.6 B1.6 B928.4 M
Slightly volatile
Net Receivables953.6 M908.2 M370.6 M
Slightly volatile
Common Stock Shares Outstanding134 M197.4 M157.6 M
Slightly volatile
Liabilities And Stockholders Equity8 B7.6 B4.5 B
Slightly volatile
Non Current Liabilities Total601.1 M748 M762.3 M
Slightly volatile
Inventory1.4 B1.3 B606.3 M
Slightly volatile
Other Current Assets195.1 M185.8 M102.7 M
Slightly volatile
Other Stockholder Equity6.3 B6 B4 B
Slightly volatile
Total Liabilities937.2 M1.5 B1.3 B
Slightly volatile
Property Plant And Equipment Gross2.3 B2.2 B1.1 B
Slightly volatile
Total Current Assets4.2 B4 B2 B
Slightly volatile
Intangible Assets243.5 M213.8 M325.3 M
Pretty Stable
Common Stock Total Equity126.8 K211.6 K158.5 K
Slightly volatile
Short Term Investments274 M248.9 M321.9 M
Slightly volatile
Short Term Debt25.2 M26.5 M219.6 M
Pretty Stable
Other Assets1.9 B1.8 B905.7 M
Slightly volatile
Long Term Debt557.4 M684.4 M653.4 M
Slightly volatile
Property Plant Equipment1.3 B1.3 B812.6 M
Slightly volatile
Other Liabilities81.8 M84.5 M100.1 M
Pretty Stable
Good Will129.1 M225.6 M151.6 M
Slightly volatile
Net Tangible Assets4.9 B4.7 B2.6 B
Slightly volatile
Long Term Debt Total730.7 M1.2 B775.3 M
Slightly volatile
Capital Surpluse3.7 B6 B3.8 B
Slightly volatile
Long Term Investments368 M599.4 M352.1 M
Slightly volatile
Non Current Liabilities Other123.8 M148.1 M115.3 M
Slightly volatile
Deferred Long Term Asset Charges309 M530.1 M360.7 M
Slightly volatile
Short and Long Term Debt339.2 M444.5 M484.5 M
Slightly volatile
Net Invested Capital5.5 B7.2 B4.8 B
Slightly volatile
Net Working Capital1.9 B3 B1.7 B
Slightly volatile
Capital Stock202.7 K219.7 K184.5 K
Slightly volatile
Capital Lease Obligations8 M6.8 M10 M
Slightly volatile

Biomarin Pharmaceutical Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization52.1 M79.6 M73.1 M
Slightly volatile
Selling General Administrative642.8 M612.1 M363.5 M
Slightly volatile
Total Revenue3.4 B3.2 B1.6 B
Slightly volatile
Gross Profit2.6 B2.5 B1.2 B
Slightly volatile
Other Operating Expenses2.8 B2.7 B1.5 B
Slightly volatile
Research Development968 M921.9 M585.4 M
Slightly volatile
Total Operating Expenses2 B2 B1.2 B
Slightly volatile
Non Recurring365.4 M689 M449.3 M
Slightly volatile
Interest Income90.4 M86.1 M36.5 M
Slightly volatile
Reconciled Depreciation110.3 M110.9 M96.4 M
Slightly volatile
Selling And Marketing Expenses460.5 M548.2 M384.3 M
Slightly volatile

Biomarin Pharmaceutical Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow990 M942.8 M514.6 M
Slightly volatile
Depreciation53.3 M79.6 M74.6 M
Slightly volatile
Capital Expenditures88.5 M103 M118.7 M
Very volatile
End Period Cash Flow1.4 B1.3 B609.6 M
Slightly volatile
Stock Based Compensation135.5 M181.4 M134 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio3.363.538324.0594
Slightly volatile
PTB Ratio1.781.87255.0263
Slightly volatile
Days Sales Outstanding10010391.1698
Pretty Stable
Book Value Per Share33.3331.738318.2904
Slightly volatile
Stock Based Compensation To Revenue0.110.05630.1
Slightly volatile
Capex To Depreciation1.231.29511.8705
Slightly volatile
PB Ratio1.781.87255.0263
Slightly volatile
EV To Sales3.153.316523.7572
Slightly volatile
Sales General And Administrative To Revenue0.20.210.187
Pretty Stable
Research And Ddevelopement To Revenue0.270.28620.9338
Slightly volatile
Capex To Revenue0.03040.0320.4179
Slightly volatile
Cash Per Share8.548.13725.393
Slightly volatile
Intangibles To Total Assets0.05130.0540.1334
Slightly volatile
Current Ratio6.795.20864.4606
Very volatile
Tangible Book Value Per Share31.0829.600415.4716
Slightly volatile
Receivables Turnover3.473.54684.2642
Very volatile
Graham Number21.6936.043338.6221
Slightly volatile
Shareholders Equity Per Share33.3331.738318.2904
Slightly volatile
Debt To Equity0.09320.09810.264
Slightly volatile
Capex Per Share0.470.53730.7356
Pretty Stable
Revenue Per Share17.6416.7968.7692
Slightly volatile
Interest Debt Per Share3.133.17064.4197
Slightly volatile
Debt To Assets0.07470.07860.1742
Slightly volatile
Operating Cycle515746674
Slightly volatile
Price Book Value Ratio1.781.87255.0263
Slightly volatile
Ebt Per Ebit0.950.90441.1195
Very volatile
Company Equity Multiplier1.141.24761.4395
Slightly volatile
Long Term Debt To Capitalization0.08490.08930.1852
Slightly volatile
Total Debt To Capitalization0.08490.08930.2
Slightly volatile
Debt Equity Ratio0.09320.09810.264
Slightly volatile
Quick Ratio5.963.49743.4291
Pretty Stable
Cash Ratio2.321.72811.5824
Slightly volatile
Cash Conversion Cycle784746524
Slightly volatile
Days Of Sales Outstanding10010391.1698
Pretty Stable
Price To Book Ratio1.781.87255.0263
Slightly volatile
Fixed Asset Turnover3.553.38191.859
Slightly volatile
Debt Ratio0.07470.07860.1742
Slightly volatile
Price Sales Ratio3.363.538324.0594
Slightly volatile
Asset Turnover0.450.42420.3137
Slightly volatile
Gross Profit Margin1.050.77130.8554
Slightly volatile
Price Fair Value1.781.87255.0263
Slightly volatile

Biomarin Pharmaceutical Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap8 B14.5 B13.2 B
Slightly volatile
Enterprise Value9.8 B15 B13.7 B
Slightly volatile

Biomarin Fundamental Market Drivers

Forward Price Earnings10.8342
Cash And Short Term Investments1.6 B

Biomarin Upcoming Events

26th of February 2024
Upcoming Quarterly Report
View
24th of April 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
26th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Biomarin Pharmaceutical Financial Statements

Biomarin Pharmaceutical investors utilize fundamental indicators, such as revenue or net income, to predict how Biomarin Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue1.2 M1.3 M
Total Revenue3.2 B3.4 B
Cost Of Revenue736.8 M773.7 M
Stock Based Compensation To Revenue 0.06  0.11 
Sales General And Administrative To Revenue 0.21  0.20 
Research And Ddevelopement To Revenue 0.29  0.27 
Capex To Revenue 0.03  0.03 
Revenue Per Share 16.80  17.64 
Ebit Per Revenue 0.17  0.17 

Pair Trading with Biomarin Pharmaceutical

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Biomarin Pharmaceutical position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Biomarin Pharmaceutical will appreciate offsetting losses from the drop in the long position's value.

Moving together with Biomarin Stock

  0.77EQ EquilliumPairCorr

Moving against Biomarin Stock

  0.47RAC Race OncologyPairCorr
  0.45OSE OSE Pharma SAPairCorr
  0.45VANI Vivani MedicalPairCorr
  0.41OB3 OPTIBIOTIX HLTH PLCPairCorr
  0.32VCYT VeracytePairCorr
The ability to find closely correlated positions to Biomarin Pharmaceutical could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Biomarin Pharmaceutical when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Biomarin Pharmaceutical - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Biomarin Pharmaceutical to buy it.
The correlation of Biomarin Pharmaceutical is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Biomarin Pharmaceutical moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Biomarin Pharmaceutical moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Biomarin Pharmaceutical can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Biomarin Pharmaceutical offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Biomarin Pharmaceutical's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biomarin Pharmaceutical Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biomarin Pharmaceutical Stock:
How To Invest In Biomarin
Details
Is Biomarin Stock a good investment?
Details
What is Biomarin Pharmaceutical's Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of Biomarin Pharmaceutical Correlation against competitors.
To learn how to invest in Biomarin Stock, please use our How to Invest in Biomarin Pharmaceutical guide.
You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Will Biotechnology sector continue expanding? Could Biomarin diversify its offerings? Factors like these will boost the valuation of Biomarin Pharmaceutical. Projected growth potential of Biomarin fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Biomarin Pharmaceutical data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth
1.243
Earnings Share
2.69
Revenue Per Share
16.165
Quarterly Revenue Growth
0.041
Return On Assets
0.0615
Understanding Biomarin Pharmaceutical requires distinguishing between market price and book value, where the latter reflects Biomarin's accounting equity. The concept of intrinsic value - what Biomarin Pharmaceutical's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Biomarin Pharmaceutical's price substantially above or below its fundamental value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
It's important to distinguish between Biomarin Pharmaceutical's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Biomarin Pharmaceutical should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Biomarin Pharmaceutical's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY